Q4 2026
Ends Dec 31, 2026
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.08
-0.08 to -0.08
No analyst count
EPS: No analyst count
May 1, 06:55 PM UTC
stable/analyst-estimates
Healthcare
Live Price
Offline$8.05
+3.74% today
Window Change
-13.53%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SELLAS Life Sciences Group, Inc. (SLS) is a Healthcare stock with a market cap of $700.00M and listed on NASDAQ. The stock last traded around $8.05 and down 13.5% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +50.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +50.0%, free cash flow +19.8% with operating margin 0.0% and ROIC -39.3%. Stock Foundry combines SLS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SLS Max Drawdown
-23.20%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SLS and SPY.
EPS Consensus
-0.08
Range -0.08 → -0.08
No analyst count
vs prior: -14.3%Revenue Outlook
$0.0B
Range $0.0B → $0.0B
No analyst count
Consensus Spread
Lower spread suggests tighter agreement across covering analysts.
Trend
Consensus average across visible periods
Trend
Average analyst revenue estimate
Timeline
Sorted by period end date. Includes both cached rows and live fallbacks from FMP.
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.